AVDL - フラメル・テクノロジ―ズ （Avadel Pharmaceuticals plc）

Avadel Pharmaceuticals plc (NASDAQ:AVDL – Get Rating) – Analysts at Lifesci Capital issued their FY2023 earnings estimates for Avadel Pharmaceuticals in a research note issued to investors on Thursday, March 30th. Lifesci Capital analyst A. Evertts expects that the company will earn ($0.64) per share for the year. The consensus estimate for Avadel Pharmaceuticals’ current […]

Avadel Pharmaceuticals plc (NASDAQ:NASDAQ:AVDL) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ETCompany ParticipantsAustin Murtagh – Stern Investor RelationsGreg Divis – Chief…

Avadel Pharmaceuticals press release (AVDL): Q4 GAAP EPS of -$0.44 misses by $0.17.Cash, cash equivalents and marketable securities were $96.5 million as of December 31, 2022.The…

Companies Reporting Before The Bell • Creative Realities (NASDAQ: CREX ) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million. • EVgo (NASDAQ: EVGO ) is likely to report quarterly loss at $0.16 per share on revenue of $21.82 million. • Edap TMS (NASDAQ: EDAP ) is likely to report quarterly loss at $0.01 per share on revenue of $17.04 million. • Marketwise (NASDAQ: MKTW ) is estimated to report quarterly earnings at $0.02 per share on revenue of $114.83 million. • Manchester United (NYSE: MANU ) is projected to report quarterly loss at $0.01 per share on revenue of $172.27 million. • Neogen (NASDAQ: NEOG ) is projected to report quarterly loss at $0.01 per share on revenue of $218.86 million. • Cazoo Gr (NYSE: CZOO ) is likely to report earnings for its fourth quarter. • Avadel Pharmaceuticals (NASDAQ: AVDL ) is likely to report earnings for its fourth quarter. • Altisource Portfolio (NASDAQ: ASPS ) is projected to report quarterly loss at $0.65 per share on revenue of $33.

• LUMRYZ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval …

Avadel Pharmaceuticals (AVDL) has submitted an amendment to the FDA requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness ((EDS)) in…

- Submitted amendment on March 1, 2023 to the LUMRYZ NDA seeking final FDA approval DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it has submitted an amendment to the U.S. Food and Drug Administration (“FDA”) requesting final approval for

Avadel (AVDL) announced Friday its plans to seek final FDA approval for sleep disorder therapy Lumryz after Jazz Pharma (JAZZ) lost an appeal in a patent dispute. Read the full story here.

DUBLIN, Ireland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15 at 1:00 p.m. ET.

- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first dose -

Avadel Pharmaceuticals (AVDL) stock rose ~13% on Wednesday after Jefferies Financial upgraded the shares to Buy from Hold on opportunity of taking market share from Jazz…

Avadel Pharmaceuticals plc (NASDAQ:AVDL) marked $7.99 per share on Friday, up from a previous closing price of $7.81. While Avadel Pharmaceuticals plc has overperformed by 2.30%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVDL fell by -19.62%, with highs and lows ranging from $10.00 to […]

Eric J Ende , Director at Avadel Pharmaceuticals (NASDAQ: AVDL ), reported a large insider buy on November 23, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Ende purchased 20,000 shares of Avadel Pharmaceuticals. The total transaction amounted to $156,050. Avadel Pharmaceuticals shares are trading down 2.13% at $7.81 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to … Full story available on Benzinga.com

Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc''s (NASDAQ: AVDL ) motion to delist the ‘963 Xyrem REMS patent. Needham says a favorable patent ruling clears a key hurdle for Lumryz, and Q3 FY23 is the most likely timeframe for full launch (vs. 4Q FY23 previously). The analyst has raised the price target to $9 from $8 with a Buy rating. Related:

As of Friday, Avadel Pharmaceuticals plc’s (NASDAQ:AVDL) stock closed at $8.03, up from $7.16 the previous day. While Avadel Pharmaceuticals plc has overperformed by 12.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVDL fell by -17.22%, with highs and lows ranging from $10.18 to $1.05, […]